Neuropathic pain is considered as an inappropriate response caused by a lesion or dysfunction in the PNS or CNS). Neuropathic pain can manifest itself as either without a stimulus (stimulus-independent pain) and/ or as pain hypersensitivity elicited after a stimulus (stimulus-evoked pain). Stimulusindependent pain includes symptoms described by the patient such as (a) continuous, burning pain (b) intermittent shooting, lancinating pain (c) some dysaesthesias. Conversely, stimulus-evoked pain describes signs the physician induces after mechanical, thermal or chemical stimulation, and usually involves hyperalgesia or allodynia. The mechanism(s) underlying neuropathic pain are not completely understood but are considered to be complex, multifactorial and to evolve over time. Neuropathic pain can be trauma (surgical and non-surgical), accidents, and exposure to toxins, infection, viruses, metabolic diseases, nutritional deficiency, ischemia, and stroke. Current research studies indicate that both peripheral and central mechanisms have been involved in pathogenesis of neuropathic pain.
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Central sensitization & plasticity. The large range of etiologies involved indicate that prevalence of NP may be high in the general population. However, epidemiological studies do not allow estimation of the overall prevalence of NP in the general population, but crude estimation in 1-3 % range have been proposed 4, 5, 6 . Recent research studies indicate that both peripheral and central mechanisms have been involved in pathogenesis of neuropathic pain 7, 8, 9 (table 1).
FIG. 1: SUMMARY OF VARIOUS MECHANISM INVOLVED IN THE PATHOPHYSIOLOGY OF NEUROPATHIC PAIN
Peripheral Sensitization: Peripheral nerve injury is associated with a local inflammatory reaction of the nerve trunk and the released inflammatory mediators sensitize the axotomized nerve fibers 10, 11, 12 .
It is well reported that peripheral or perineural inflammation as measured by plasma extravasation or increased capillary permeability which causes inflammatory cell infiltrate leading to the release of various pronociceptive and pro-inflammatory mediators 13, 14 .
Most importantly, neurogenic inflammation has also been reported in experimental models of nerve injury that implicates increased capillary permeability, leading to plasma leakage of proinflammatory and pronociceptive mediators at the local as well as adjacent sites to tissue injury 13, 15, 16 . This is accompanied by enhanced release of substance P(SP) and calcitonin gene-related peptide (CGRP) in the control of vascular tone following nerve injury 13, 16 . Thus, the pro-inflammatory mediators might be involved in the development and maintenance of neuropathic hyperalgesia. The role of the bradykinin receptors is particularly interesting in this regard. Bradykinin is released as a result of tissue damage, and has been mainly associated with the inflammatory hyperalgesia 19 .
However, recent finding also suggest its role in neuropathic pain. In a recent study, peripheral nerve injury caused a, de novo, expression of the B1 receptor, which is normally absent in neuronal cell. Moreover, the antagonists of bradykinin receptors had antihyperalgesic effects 20 . The PGs including PGE2 and PGI2 (also known as prostacyclin) are also rapidly produced following tissue injury and are major contributors to peripheral sensitization 21, 22, 23, 24 . It has been reported that COX inhibitors, which inhibit the production of PGs, attenuate the thermal and mechanical hyperalgesia in animal model of neuropathic pain 21, 22, 23, 24 .
Central Sensitization: Central sensitization represents a state of heightened sensitivity of dorsal horn neurons such that their threshold of activation is reduced, and their responsiveness to a synaptic input is augmented 25 . There are two forms of central sensitization.
The first form is an activity-dependent form that is rapidly induced within seconds by afferent activity in nociceptors and which produces changes in synaptic efficacy that last for tens of minutes as a result of the phosphorylation and altered trafficking of voltage-and ligand-gated ion channel receptors 17, 26 . The second one is transcription-dependent form that takes some hours to be induced but outlast the initiating stimulus for prolonged periods 27 .
Under normal conditions the activity-dependent form of central sensitization is produced only following the activation of small caliber Aδ and C fiber afferents by a noxious or tissue damaging stimulus. After peripheral nerve injury, C-fiber input may arise spontaneously and drive central sensitization. In addition, the phenotypic changes that occur in Aβ fibers after nerve injury leads to central sensitization and repeated light touch after nerve injury begin to produce central sensitization 28 .
The activity dependent form of central sensitization is responsible for generating secondary pinprick hyperalgesia and dynamic tactile allodynia 29 . In addition to events such as lowering of activation thresholds of spinal neurons, central sensitization is also characterized by the appearance of 'wind-up'. Wind-up is characterized by an increasing response to repeated C-fiber stimulation, and may contribute to hyperalgesia 30 .
Inflammation: Inflammation is the body defensive mechanism against injury to body tissues. Inflammation can be acute or chronic depending upon the severity of the trauma 25, 31 . Inflammation may release or generate a variety of pro-inflammatory 32 and/or pronociceptive mediators which may produce pain, hyperalgesia, or allodynia that develop as an acute response to a local inflammatory insult 33 . Inflammation leads to increased capillary permeability, perivascular leakage of plasma protein, infiltration and/or migration of neurophils to the site of injury 31, 34 . In general terms, acute inflammation is associated with high levels of polymorphonuclear cells, particularly neutrophils, whereas chronic or adaptive immune inflammation has higher levels of mononuclear cells, macrophages, T-and Blymphocytes 35 ( Fig. 2) .
A. Peripheral inflammatory cells:
1. Mast Cells: Mast cells are crucial players in allergic reactions and important initiators of innate immunity 36 . After a partial ligation of the sciatic nerve (PNL), the resident population of mast cells in the peripheral nerve are activated and degranulated at the site of nerve damage 37 . They release proinflammatory mediators, including histamine, serotonin, cytokines and proteases 36, 38 . Histamine seems to be a key mast cell mediator, having sensitizing effects on nociceptors 39 , and is capable of inducing severe burning pain when applied to the skin of patients suffering from postherpetic neuralgia 40 . In addition, neuronal histamine receptors are upregulated after a crush injury to the sciatic nerve 41 . These studies suggest that activated mast cells contribute directly to neuropathic pain by releasing algogenic mediators after degranulation. Mast cells may also contribute indirectly by enhancing the recruitment of other key immune cell types which, in turn, release pronociceptive mediators (Fig. 2 ).
2. Neutrophils: Neutrophils (or polymorpho-nuclear leukocytes) are normally the earliest inflammatory cells to infiltrate damaged tissue and dominate the acute inflammatory stage 42, 43 . As well as being capable of phagocytosis, they release a variety of proinflammatory factors, including cytokines and chemokines, which, in turn, activate and attract other inflammatory cell types, most no tably macrophages 42, 43 . Neutrophils are almost absent in the intact, uninjured nerve. Significant infiltration of neutrophils has been observed at the site of nerve lesion in a number of rodent neuropathy models, including PNL 37 , sciatic nerve crush 44 , and chronic constriction injury 45 (CCI). Perkins and Tracey have demonstrated that preventive, rather than curative, depletion of circulating neutrophils, after systemic administration of a selective cytotoxic antibody, reduced the development of thermal hyperalgesia.
Thus, neutrophils may be important during the early stages of neuropathic pain development, releasing mediators such as chemokines at the injury site that initiate macrophage infiltration and activation 46 . It is likely that other leukocyte populations (i.e. eosinophils and basophils) are involved in the early events after nerve injury, but little is known about their potential role in the production of neuropathic pain.
Macrophages: Macrophages are the key immune
and phagocytic cell in the peripheral nerve. They are recruited in response to peripheral nerve injury, such as inflammation of and/or loss of axons, myelin, or both. Their main function is to phagocytose foreign material, microbes, and other leukocytes as well as to play a critical role in removing injured and dying tissue debris during Wallerian degeneration 43, 47 .
The recruitment and activation of macrophages within the peripheral nerve is an extremely specific and well-modulated mechanism, involving several proinflammatory mediators and other cell types 48 . Macrophage function has been examined in various models of neuropathic pain, including CCI 49 , PNL 50 and spinal nerve ligation 51 (SNL).
A reduction in neuropathic pain behaviors correlating with an attenuation of macrophage recruitment into the damaged nerve 52 . It is likely that they contribute through several mechanisms, including the release of pronociceptive mediators. Macrophages are recruited by monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1 α) and the IL-1β ISSN: 0975-8232
Available online on www.ijpsr.com 3534 53 , the latter two are released by neutrophils. Macrophages secrete prostaglandins, including PGE2 and PGI2 54, 55 , which sensitize primary afferent directly. Prostaglandin release by macrophages is strongly implicated in neuropathic pain since inhibition of COX, an enzyme responsible for PGs synthesis, relieves hyperalgesia in nerveinjured rats 56 and COX-2 is up-regulated in macrophages in the injured nerve 21, 22, 23 .
T-lymphocytes:
Lymphocytes are divided into two subpopulation: B lymphocytes, responsible for antibody production, and T lymphocytes, which are mediators of cellular immunity (T cells), or natural killer cells. After the identifition of both T Cells and natural killer cells at the site of nerve injury in several rodent models, the involvement of T cells in NP was proposed 57 . Further, after transection of a spinal nerve , both cell types appear in the adjacent, uninjured DRG, although in lower numbers 58 . The invasion of DRG is apparently triggered by retrograde signals from the peripheral nerve. Finally, sural nerve biopsies taken from neuropathic pain patients suggest that T-cell infiltration may be temporally correalated to hyperalgesia 59 .
Schwann cells:
Following peripheral nerve injury, Wallerian degeneration distal to the injury site results in the production of cytokines, such as TNF-α 60 . Schwann cells produce TNF-α expression in injured and non-injured nerves,IL-1β and neurotrophins e.g., NGF. IL-1β regulates synthesis of NGF in non-neuronal cells of the rat sciatic nerve, by Schwann cell and macropages. There have been reports where TNF-receptors immunoreactivity is also observed in Schwann cells and macrophages 61 .
The compelling evidence that Schwann cells are involved in the production of neuropathic pain comes from a series of studies which demonstrate neuroprotective and anti-nociceptive effects of erythropoietin after both CCI and crush-induced lesions 62 . Furthermore, they were able to correlate these findings with a reduction in levels of TNF-α immunoreactivity in Schwann cells 63 .
NOCICEPTIVE SENSITIZATION

FIG. 2: VARIOUS MEDIATORS OF NEUROPATHIC PAIN
After 1. Microglia: Among the non-neuronal cells, microglia are generally considered the immune cells of the CNS. They are known for their response to any kind of pathological insult for which the reaction is termed microglial activation 64, 65 . Microglia is, however, known to play a crucial role in the maintenance of neuronal homeostasis in the CNS, and the microglia production of immune factors is believed to play an important role in nociceptive transmission 66 . There is increasing evidence that uncontrolled activation of microglial cells under NP conditions induces the release of proinflammatory cytokines 67, 68, 69 (IL-1β, IL-6, TNF-α), complement components (C1q, C3, C4, C5, C5a) and other substances that facilitate pain transmission ( fig. 3) .
Pharmacological attenuation of glial activation represents a novel approach for controlling NP 70 . Glial cells usually represent 70% of the cells in the CNS under normal conditions, and microglia represents 5-10% of glia 71 . The most characteristic feature of microglia is their rapid activation in the CNS in response to pathological events, including trauma, ischemia, inflammation, hypoxia, neurodegeneration and viral or bacterial infection. After activation, microglial cells change morphology from a resting, ramified shape into an active, amoeboid shape 72 .
Numerous studies in the recent years suggest an important role of microglial activation observed during NP 73 . However, the role glia in the cellular mechanisms underlying the symptoms of neuropathic pain, such as hyperalgesia or allodynia, is not clear 74 . Microglial cells secrete a large variety of substances, including growth factors, cytokines, complement components, lipid mediators, extracellular matrix components, enzymes, free radicals, neurotoxins, NO, and PGs 75, 76 . Furthermore, a transient neuropathic state in naïve rats can be induced by intrathecal injection of ATP-stimulated microglia 77 . 2. Astrocytes: Astrocytes, developmentally derived from the neuroectoderm, are the most abundant glial cell type in the CNS. In addition to their neuron-supportive functions, astrocytes also directly alter neuronal communication because they completely encapsulate synapses and are in close contact with neuronal somas 78 .
FIG. 3: SPINAL CORD GLIA REGULATION IN THE DEVELOPMENT OF EXAGGERATED PAIN
There are large number of studies which explore that astrocytic responses are more consistent with the maintenance of pain behavior in neuropathic pain models is delayed 79 and can be reduced by glial modulators 80 (e.g., propentofylline and minocycline). Most studies demonstrate that spinal microglial activation precedes astrocyte activation 81 , but when established the level of astrocyte activation appears to be closely correlated with pain behaviors in different neuropathic pain models 82 .
C. Immune factors in neuropathic pain conditions:
1. Cytokines: The mediators released by inflammatory and immune cells may act directly to sensitize or activate neurons (nociceptors in the periphery or dorsal horn neurons in the spinal cord). Alternatively, they may act on a non-neuronal cell, which on activation releases another mediator that does act directly on the neuron. There mediators form a long and increasing list that includes bradykinin, eicosanoids, cytokines, neurotrophins and reactive oxygen species 83 .
Cytokines are small regulatory protein that mediate interactions between cells over relatively short distances. They are mostly involved in responses to disease or infection 84 . Many of them are known as interleukins, a mediator released by one leukocyte and acting on another , but they are synthesized by most cell types. Several are pro-inflammatory, such as IL-1β, IL-6 and TNF, while others such as IL-10 are anti-inflammatory. These pro-inflammatory cytokines contribute to the mechanism of neuropathic pain 85, 86 . These cytokines are also induced in the CNS 87 . The algesic effects of proinflammatory cytokines are often indirect, so that they may not act directly on the nociceptor but they induce the expression of agents (such as PGE2) that themselves sensitize nociceptors 51, 86 .
2. Interleukin-1β: IL-1β is the one of many pluripotent pro-inflammatory cytokines. It is produced and secreted by immune cells including macrophages, monocytes, and microglia under conditions of stess. IL-1β has been identified as one of many algogenic agents that may play a role in neuropathic pain. In the periphery, IL-1β itself results in prolonged hyperalgesia and allodynia after intraplantar 88 , intraperitoneal 89 and intrathecal 90 administration.
The mechanism of action of IL-1β in periphery is still not clear. But several studies have shown that binding of IL-1β to its receptor IL1-RI on the cell surface initiates several signaling events, such as translocation of NF-κB into the nucleus. NF-κB then upregulates transcription of several genes, including COX-2, iNOS, TNF-α, IL-1β and IL-6 91, 92 . IL-1β may act directly as well indirectly on nociceptors. IL-1 is implicated in neuropathic pain since IL-1α and IL-1β are both upregulated in injured peripheral nerve 93 and also in spinal cord 94 .
3. Tumor Necrosis Factor-α: Tumor Necrosis Factor (TNF, TNFSF2, formerly and TNF-α ) is a member of a large super family of protein, which have an unusual trifold symmetry. There is an equally large super family of receptors; the receptors activated by TNF-α are the constitutively expressed TNFR1 (TNFRSF1A, p22-R ) and the inducible TNFR2( p75-R) 95 .
TNFR1 is linked to pathways for cell death, whereas TNFR2 is not 96 . However, activation of either receptor results in p38 MAP kinase signaling 97 , translocation of NF-κB to the nucleus and activation of COX-2-dependent prostanoids release 98 . TNF is constitutively expressed in cutaneous mast cell 99 , but, in injury or inflammation, it may be released by other cell including neutrophils and macrophages. Injury of the sciatic nerve leads to upregulation of TNF-α and its receptors in the nerve 100 , this upregulation is found mainly in Schwann cell and endothelial cell 101 .
Nerve injury also leads to increased TNF-α expression in the dorsal horn of the spinal cord and in the locus coeruleus and hippocampus 102 . Inhibiting TNF-α synthesis with thalidomide or treatment with anti-TNF-α neutralizing antibodies at the time of nerve injury blocked the development of hyperalgesia and allodynia in the these animal models 103, 104 . Furthermore, treatment with etanercept, a recombinant TNF-α receptor (p75)-Fc fusion protein that acts as a TNF-α antagonist, reversed established hyperalgesia in mice with a chronic constriction injury of the sciatic nerve 103 .
4. Nerve Growth Factor: Neurotrophic factors regulate the long-term survival, growth or differentiated function of discrete populations of neurons. The prototypical neurotrophin is NGF. Critical evidence for a role of NGF in pain production was the identification of a mutation in the gene encoding trkA, the high-affinity receptor for NGF. This mutation in trkA leads to congenital insensitivity to pain 105 by disrupting NGF signaling and demonstrates its importance for normal nociceptive functioning.
The role of NGF in pain signaling is now well understood. Small doses of NGF produce pain and hyperalgesia in adult animals and humans. In rodents, thermal and mechanical hyperalgesia develop after systemic NGF administration 106 . NGF produces sensitization of nociceptors both directly (after activation of trkA on nociceptors) and indirectly, mediated via other peripheral cell types. The direct mechanisms involve both altered gene expression and posttranslational regulation of receptors and ion channels, including TRPV 1107 and tetrodotoxin-resistant N a+ channels 108 . Indeed, NGF over expressing mice display a marked hypersensitivity to both mechanical and thermal stimuli after CCI, suggesting that excess NGF may enhance neuropathic pain behaviors 109 . Several groups have therefore tested the use of anti-NGF treatment in models of neuropathic pain. Anti-NGF antibodies are able to delay the development of neuropathic pain behaviors after both CCI 110 , and SNL 111 5 . Chemokines: Chemokines are considered a large family of secreted proteins that are found to be chemotactic for leukocytes 112 . Evidences exist that, CCL2 is upregulated exclusively in neurons of the DRG following peripheral nerve injury 113 , while it is expressed by neurons and microglia in the spinal cord 114 . A spatial and temporal relationship between CCL2 expression and spinal glial activation following nerve injury is evident 114 , suggesting that neuronal CCL2 may serve as a trigger for spinal microglia activation 115 .
6. Prostanoids: It has been established that the PGs also contribute to nociception at the level of the spinal cord 116 . Various studies have shown that mechanical hyperalgesia in nerve-injured rats was alleviated for up to 10 days by subcutaneous injection of indomethocin (a classic inhibitor of COX-1/2) into the affected hind paw. Subcutaneous injection of selective COX-2 inhibitors or an EP1 receptor blocker relieved thermal as well as mechanical hyperalgesia, but with a shorter time course 117 . This shows that there is increased expression of PGs in the region of the nerve lesion that contributes to neuropathic pain 118 .
Several animal models of neuropathic pain showed that the number of COX-2 immunoreactive cells was dramatically increased in the region of the nerve lesion 119 and increased levels of PGE2 are found in the injured nerves. Furthermore, cells immunoreactive for EP receptors are found in the injured nerve, but not in normal intact nerve. Observation, based on several animal models of sciatic nerve injury, support the idea that upregulation of COX-2 and EP receptors in the injured nerve contribute to neuropathic pain.
Nitric Oxide(NO) and Reactive Oxygen Species (ROS):
Reactive oxygen species such as NO and superoxide play important roles in inflammatory and immune responses, including defense mechanisms against invading microbes 120 . They are released by a number of cell types, including neutrophils (Zuo et al., 2003) and macrophages 121 as well as astrocytes 122 and microglia 123 .
NO is a diffusible free radical that is synthesized by three distinct NO synthases (NOS), neuronal and endothelial forms (nNOS and eNOS) are constitutive, while the inducible form (iNOS) is upregulated in immune cells. Once released, NO can react with superoxide radicals to form peroxynitrite, which is toxic and may cause tissue damage.
NO play important role in nociception 124 . It causes pain when injected into the skin of human subjects 125 and contributes to peripheral hyperalgesia in the skin and joints, probably by contributing to PGE2-induced sensitization of primary afferents 126 .
NO is also implicated in central mechanisms of hyperalgesia where nNOS and NO form part of a second messenger cascade involving cyclic GMP and may be partly responsible for sensitization of spinal neurons 127 . In rats with a chronic constriction injury of the sciatic nerve, iNOS is induced in macrophages and Schwann cells at the injury site and distal to it 128 .
Treatment with a non-specfic NOS inhibitor (L-NAME) alleviated hyperalgesia and blocked ectopic mechanosensitivity of injured A-fibers. NO also plays a role in central mechanisms of neuropathic pain so that, in nerve injured rats, intrathecal delivery of the NOS inhibitor L-NAME produced a dose-dependent reduction of thermal hyperalgesia 129 .
Growing body of evidence indicates that ROS are also implicated in neuropathic pain. ROS also contribute to mechanical allodynia, which is relieved by SOD in an inflammatory model of neuropathic pain 130 . Anticonvilsant drug such as carbamazapine (Tegretol ® ) act through membrane stabilization was also approved by the FDA for the treatment of trigeminal neuralgia 133 .
Antidepressant drug duloxetine (Cymbalta ® ) that act through selective serotonin and nor-epinephrine reuptake inhibition has recently been approved by the FDA for treatment of diabetic neuropathic pain (DNP). Another antiepileptic drug, pregabalin (Lyrica ® ) was also launched in the treatment of DNP in 2004 134 . Other agents includes systemic local anesthetic, anticonvulsants like lamotrigine, tiagabine etc, antidepressants like selective serotonin reuptake inhibitors (SSRI), opioid analgesics, NMDA receptor analgesics are in preclinical and various phases of clinical trials. Despite these many therapeutic options, the treatment of neuropathicpain pain is not fully effective and often unsatisfactory and severely hampered by dose-limiting side effects which limit the treatment.
Thus, there is unmet need to understand disease pathogenesis, identify and characterize novel targets, and develop newer agents which act at one or more sites in the pathogenesis of neuropathic pain. Although important, these peripheral processes do not occur in isolation from central neuroinflammation.
Together, these neuroimmune interactions seem essential for the production of neuropathic pain symptoms.
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